Progress in preconditioning regimen of autologous hematopoietic stem cell transplantation for treatment of multiple myeloma
10.3760/cma.j.issn.1009-9921.2017.05.018
- VernacularTitle:自体造血干细胞移植治疗多发性骨髓瘤预处理方案的研究进展
- Author:
Yong XU
- Keywords:
Multiple myeloma;
Hematopoietic stem cell transplantation;
Transplantation conditioning
- From:
Journal of Leukemia & Lymphoma
2017;26(5):313-317
- CountryChina
- Language:Chinese
-
Abstract:
High-dose melphalan (Mel) is considered as a current standard preparative regimen in autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Irradiation in total body (TBI) combined with Mel is not superior to Mel alone, and the adverse reactions are increased at the same time. The efficacy of 200 mg/m2 Mel is much better than that of 100-140 mg/m2 Mel in young patients. Several regimens including MelBU, TBC, BCV, MET, MTC, MelBCNU, VMel, MTC as well as bendamustine have similar treatment outcomes compared with 200 mg/m2 Mel. Other strategies need to be evaluated in different trials.
